Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
NCT05491616
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
77
Enrollment
OTHER
Sponsor class
Conditions
Esophageal Cancer
Interventions
DRUG:
Nivolumab
Sponsor
Erasmus Medical Center